Catalyst Pharmaceutical Inc (NASDAQ: CPRX) has reported E.P.S. of $0.20 for its first fiscal quarter (ending March 31) versus $0.28 for the same period a year ago — a decline of -29%. Relative to the consensus estimate of $0.47, this was a shortfall of $-0.27. For the latest four quarters through March 31, E.P.S. were $0.60 compared to $0.95 a year ago — a decline of -37%.
Recent Price Action
On 5/8/24, Catalyst Pharmaceutical Inc (NASDAQ: CPRX) stock declined by -2.8%, closing at $14.72. However, this decline was accompanied by below average trading volume at 80% of normal. Relative to the market the stock has been strong over the last nine months but has declined -2.2% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, CPRX is expected to continue to be a major Value Builder.
Catalyst Pharmaceutical has a current Value Trend Rating of A (Highest Rating). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Catalyst Pharmaceutical has a neutral Power Rating of 58 but a very high Appreciation Score of 94, and the Highest Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment